Add a producer of inhalable migraine headache treatments to its Botox and other products and you have a winning company.
Cramer is bullish on Synovus, Unilever and Cree but urges caution on Map Pharmaceuticals and KB Homes.
A list of stocks with drugs expecting FDA decisions in 2013
Biotech columnist Adam Feuerstein answers readers' questions about health-care companies
Why is it taking so long for FDA to respond to MAP Pharma's Levadex resubmission?
©1996-2018 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.